Avance Clinical Acquires C3 Research Associates

BP Elements, BioPharm International's BP Elements, September 2022, Volume 1, Issue 9

Avance Clinical’s acquisition of C3 Research Associates expands its CRO services to North America.

Avance Clinical, an Australia-based contract research organization (CRO) for biotechs, announced on Sept. 6, 2022 that it has expanded its services into North America with the acquisition of C3 Research Associates, a US-based CRO partner company. The acquisition will enable Avance to offer biotech clients an easier transition from early phase to later phase studies.

With the acquisition, Avance will have the capability to progress early phase studies in Australia and New Zealand into the United States, allowing biotech clients to continue their clinical development programs while retaining the same CRO services. This efficiency would reduce time and cost and allow for biotech companies to deliver quality data that will be acceptable to FDA.

The company intends to make significant investments in its US operations, including growing its team to more than 120 people and leveraging deep industry experience across a broad range of therapeutic areas, specifically oncology, according to a company press release.

“Avance Clinical has been working with C3 Research Associates in recent years, and they share a similar culture and focus on customer service and clinical excellence. This strong relationship made C3 Research Associates a natural acquisition choice for Avance Clinical’s expansion plans into North America. The due diligence process has taken more than [six] months, and we are excited to now welcome our US team and offer the GlobalReady model for our clients,” said

Yvonne Lungershausen, CEO of Avance Clinical, in the press release.

Source: Avance Clinical